Health Industry Manufacturers Association (HIMA) urges revamp of Medicare policies
This article was originally published in Clinica
Executive Summary
Medicare should pay for costs of care associated with medical device clinical trials approved by the FDA, recommends industry association HIMA. The current practice to deny reimbursement for care involving a device not approved for marketing "has a tragic consequence of delaying and, in some cases, denying Medicare beneficiaries access to the very innovations that are helping other patients lead longer, more productive lives", says HIMA executive vice-president Ted Mannen.